Abstract
The individualized treatment of type 2 diabetes mellitus, using various glucagon-like peptide receptor agonists (GLP1RAs), has recently been described. As experience with existing GLP1RAs grows, and as newer molecules in the development pipeline continue to progress, interest related to these drugs continues to grow. This article describes a person-centered approach, using the bio-psychosocial model of health, to help individualized decision making related to choice of GLP1RA. It utilizes an evidence-based approach to discuss various biomedical and psychosocial factors which may influence choice of GLP1RA.